Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Xie, Xiaoxue ^a   Wang, Hui ^a   Jin, Hekun ^a   Ouyang, Shuyu ^a   Zhou, Jumei ^a   Hu, Jun ^a   Xi, Xuping ^a   Luo, Junming ^a   Zhang, Yingying ^b   Hu, Bingqiang ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Nasopharyngeal carcinoma; p53 codon 72 polymorphism; pAkt; Radiotherapy

Indexed keywords

PARAFFIN; PROTEIN KINASE B; PROTEIN P53;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISTANT METASTASIS; ENZYME PHOSPHORYLATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CODON; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84877264216     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-117     Document Type: Article

References (50)

1. Min HQ. Nasopharyngeal carcinoma. Epidemiology 1996, 280-285. Beijing, China: People's Medical Press, Gun GY.
2. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma:results of ameta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002, 25:219-223. 10.1097/00000421-200206000-00002, 12040275.
3. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004, 22:4604-4612. 10.1200/JCO.2004.10.074, 15542811.
4. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100. 116039, 9891044.
5. Dumont P, Leu J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365. 10.1038/ng1093, 12567188.
6. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004, 23:3328-3337. 10.1038/sj.onc.1207428, 15077186.
7. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004, 108:196-199. 10.1002/ijc.11548, 14639602.
8. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006, 38:1133-1141. 10.1038/ng1879, 16964264.
9. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Iencke JK, Christiani DC. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000, 9:1037-1042.
10. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C, Kimura J, Maeno G, Hirose H, Eguchi T, Saito D, Ohki M, Yokota J. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 2005, 114:730-737. 10.1002/ijc.20790, 15609317.
11. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Greco G, Mussi A, Fontanini G. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncol Rep 2008, 19:771-773.
12. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, Von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H. Clin. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005, 11:5098-5103. 10.1158/1078-0432.CCR-05-0173, 16033823.
13. Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Brigliadori G, Amadori D. Bonafe M :Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumor Biol 2008, 29:145-151.
14. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 2009, 64:355-360. 10.1007/s00280-008-0879-3, 19052714.
15. Zhuo XL, Cai L, Xiang ZL, Zhuo WL, Wang Y, Zhang XY. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res 2009, 40:299-305. 10.1016/j.arcmed.2009.03.006, 19608020.
16. Jung IL, Kang HJ, Kim KC, Kim IG. PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-small cell lung cancer. Int J Mol Med 2010, 25:517-523.
17. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 2008, 19:319-328.
18. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006, 20:267-275. 10.1101/gad.1363206, 16452501.
19. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002, 21:1299-1303. 10.1038/sj.onc.1205181, 11850850.
20. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002, 277:21843-21850. 10.1074/jbc.M109745200, 11923280.
21. Meek DW. The p53 response to DNA damage. DNA Repair (Amst) 2004, 3:1049-1056.
22. Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci USA 2008, 105:7785-7790. 10.1073/pnas.0703423105, 2409394, 18505846.
23. Suvasini R, Somasundaram K. Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy. Oncogene Oncogene 2010, 29:3605-3618.
24. Huang WC, Chen CC. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 2005, 25:6592-6602. 10.1128/MCB.25.15.6592-6602.2005, 1190347, 16024795.
25. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004, 108:43-48. 10.1007/s00401-004-0860-0, 15088099.
26. Salvioli S, Bonafe M, Barbi C, Storci G, Trapassi C, Tocco F, Gravina S, Rossi M, Tiberi L, Mondello C, Monti D, Franceschi C. p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 2005, 4:1264-1271. 10.4161/cc.4.9.1978, 16082224.
27. Den Reijer PM, Maier AB, Westendorp RG, Van Heemst D. Influence of the TP53 codon 72 polymorphism on the cellular responses to X-irradiation in fibroblasts from nonagenarians. Mech Ageing Dev 2008, 129:175-182. 10.1016/j.mad.2007.12.006, 18272203.
28. Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997, 57:3562-3568.
29. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402. 10.1016/S1535-6108(03)00079-5, 12726864.
30. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000, 25:47-54. 10.1038/75586, 10802655.
31. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001, 22:515-517. 10.1093/carcin/22.3.515, 11238194.
32. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462. 10.1016/S1044579X02000883, 12450731.
33. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 1998, 393:229-234. 10.1038/30400, 9607760.
34. Lopez-Lizarraga E, Sanchez-Corona J, Montoya-Fuentes H, Bravo-Cuellar A, Campollo-Rivas O, Lopez-Demerutis E, Morgan-Villela G, Arcaute-Velazquez F, Monreal-Martinez JA. Human papillomavirus in tonsillar and nasopharyngeal carcinoma: isolation of HPV subtype 31. Ear Nose Throat J 2000, 79:942-944.
35. Mirzamani N, Salehian P, Farhadi M, Tehran EA. Detection of EBV and HPV in nasopharyngeal carcinoma by in situ hybridization. Exp Mol Pathol 2006, 81:231-234. 10.1016/j.yexmp.2006.04.006, 16787643.
36. Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A, Worden FP, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, Stoerker J, Walline H, Carey TE, Bradford CR. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010, 32:562-567. 2855405, 19757421.
37. Faccioli S, Cavicchi O, Caliceti U, Rinaldi Ceroni A, Chieco P. Cell proliferation as an independent predictor of survival for patients with advanced nasopharyngeal carcinoma. Mod Pathol 1997, 10:884-894.
38. Genc E, Hosal AS, Gedikoglu G, Ozyar E, Sozeri B. Prognostic value of p53, proliferating cell nuclear antigen, and Ki-67 expression in undifferentiated nasopharyngeal carcinomas. Otolaryngol Head Neck Surg 2000, 122:868-873. 10.1016/S0194-5998(00)70016-7, 10828801.
39. Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O'Sullivan B, Cummings BJ, Warde P, Liu FF. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002, 94:1997-2006. 10.1002/cncr.0679, 11932902.
40. Tsai ST, Jin YT, Leung HW, Wang ST, Tsao CJ, Su IJ. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res 1998, 18:2849-2854.
41. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003, 25:864-872. 10.1002/hed.10307, 12966511.
42. Masuda M, Shinokuma A, Hirakawa N, Nakashima T, Komiyama S. Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 1998, 20:640-644. 10.1002/(SICI)1097-0347(199810)20:7<640::AID-HED11>3.0.CO;2-K, 9744466.
43. Wang LF, Chai CY, Kuo WR, Tai CF, Lee KW, Ho KY. The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma. Acta Otolaryngol 2006, 126:769-774. 10.1080/00016480500469545, 16803719.
44. Kouvidou C, Stefanaki K, Dai Y, Tzardi M, Koutsoubi K, Darivianaki K. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. Anticancer Res 1997, 17:2615-2619.
45. Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003, 23:7096-7107. 10.1128/MCB.23.20.7096-7107.2003, 230310, 14517281.
46. Yang H, Zhao R, Lee MH. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol Cancer Ther 2006, 5:253-860.
47. Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, Zhang PF, Li MY, Li JL, Yi H, Peng F, Chen ZC, Xiao ZQ. Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem 2009, 106:858-866. 10.1002/jcb.22051, 19160382.
48. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009, 4:761-767. 10.1097/JTO.0b013e3181a1084f, 19404218.
49. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805. 10.1038/nrc1455, 15510160.
50. Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J, Tashiro F, Tanuma S, Sakai R, Kawase T, Kitabayashi I, Taya Y, Ohki R. Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem 2011, 286:18251-18260. 10.1074/jbc.M110.208587, 3093897, 21454683.